【结 构 式】 |
【分子编号】41188 【品名】2-hydrazinoethylamine; 2-hydrazino-1-ethanamine 【CA登记号】 |
【 分 子 式 】C2H9N3 【 分 子 量 】75.11368 【元素组成】C 31.98% H 12.08% N 55.94% |
与该中间体有关的原料药合成路线共 2 条
合成路线1
该中间体在本合成路线中的序号:(II)The cyclization of 9-fluoro-6-(tosyloxy)-5,10-dihydrobenzo[g]isoquinoline-5,10-dione (I) with 2-aminoethylhydrazine (II) gives 2-(2-aminoethyl)-5-(tosyloxy)indazolo[4,3-gh] isoquinolin-6(2H)-one (III), which is finally condensed with N,N-dimethylethylene-1,2-diamine (IV) to afford the title compound.
【1】 Gallagher, C.E.; Maresch, M.J.; Krapcho, A.P.; et al.; 6,9-Disubstituted benz[g]isoquinoline-5,10-diones, key intermediates for the synthesis of antitumor 2,5-disubstituted-indazolo[4,3-gh]isoquinoline-6(2H)-ones (9-aza-anthrapyrazoles). 25th Natl Med Chem Symp (June 18, Univ. Michigan, Ann Arbor) 1996, Abst. 15. |
【2】 Menta, E.; et al.; Synthesis and antitumor evalution of 2, 5-disubstituted-indazolo[4, 3-gh]isoquinoline-6(2H)-ones (9-aza-anthrapyrazoles). 211th ACS Natl Meet (March 24-28, New Orleans) 1996, Abst MEDI 076. |
【3】 Krapcho, A.P.; Menta, E.; Antitumor aza-anthrapyrazoles. Drugs Fut 1997, 22, 6, 641. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 41185 | 9-fluoro-5,10-dioxo-5,10-dihydrobenzo[g]isoquinolin-6-yl 4-methylbenzenesulfonate | C20H12FNO5S | 详情 | 详情 | |
(II) | 41188 | 2-hydrazinoethylamine; 2-hydrazino-1-ethanamine | C2H9N3 | 详情 | 详情 | |
(III) | 41189 | 2-(2-aminoethyl)-6-oxo-2,6-dihydroindazolo[4,3-gh]isoquinolin-5-yl 4-methylbenzenesulfonate | C22H18N4O4S | 详情 | 详情 | |
(IV) | 14481 | (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carbothioic S-acid | C21H26F2O4S | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号:(II)The reaction of aziridine (I) with hydrazine gives aminoethylhydrazine (II) (1), which is then cyclized with ethyl 2,3-diphenylpropionimidate hydrochloride (III) in ethanol. (1,2)
【1】 Trepanier, D.L. (Dow Chem. Co.); US 3471486 . |
【2】 Trepanier, D.L.; et al.; Vitrase approved by FDA as spreading agent; phase III results in vitreous hemorrhage also presented. J Med Chem 1969, 12, 2, 257. |
【3】 Castaner, J.; Hillier, K.; DL - 262. Drugs Fut 1979, 4, 3, 196. |
Extended Information